Susceptibility of Candida albicans and other yeasts to fluconazole: Relation between in vitro and in vivo studies

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

In vitro studies of fluconazole have demonstrated that test results can be influenced by several test conditions, including medium composition, pH, and size of the starting fungal inoculum. In studies with Candida albicans, a few isolates have been identified that are markedly more resistant than other strains of the same species; in several in vivo studies of experimental infections, the more resistant isolates have caused infections less susceptible to fluconazole treatment. These findings corroborate a relation between in vitro and in vivo results. With further work it should be possible to define standard methods for use by clinical laboratories in determining fungal susceptibility to fluconazole.

Original languageEnglish (US)
JournalReviews of Infectious Diseases
Volume12
Issue numberSUPPL. 3
StatePublished - 1990

Fingerprint

Fluconazole
Candida albicans
Yeasts
Infection
In Vitro Techniques

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

@article{4b45cb3f686e49ee98e75a4c33923fe7,
title = "Susceptibility of Candida albicans and other yeasts to fluconazole: Relation between in vitro and in vivo studies",
abstract = "In vitro studies of fluconazole have demonstrated that test results can be influenced by several test conditions, including medium composition, pH, and size of the starting fungal inoculum. In studies with Candida albicans, a few isolates have been identified that are markedly more resistant than other strains of the same species; in several in vivo studies of experimental infections, the more resistant isolates have caused infections less susceptible to fluconazole treatment. These findings corroborate a relation between in vitro and in vivo results. With further work it should be possible to define standard methods for use by clinical laboratories in determining fungal susceptibility to fluconazole.",
author = "Galgiani, {John N}",
year = "1990",
language = "English (US)",
volume = "12",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Susceptibility of Candida albicans and other yeasts to fluconazole

T2 - Relation between in vitro and in vivo studies

AU - Galgiani, John N

PY - 1990

Y1 - 1990

N2 - In vitro studies of fluconazole have demonstrated that test results can be influenced by several test conditions, including medium composition, pH, and size of the starting fungal inoculum. In studies with Candida albicans, a few isolates have been identified that are markedly more resistant than other strains of the same species; in several in vivo studies of experimental infections, the more resistant isolates have caused infections less susceptible to fluconazole treatment. These findings corroborate a relation between in vitro and in vivo results. With further work it should be possible to define standard methods for use by clinical laboratories in determining fungal susceptibility to fluconazole.

AB - In vitro studies of fluconazole have demonstrated that test results can be influenced by several test conditions, including medium composition, pH, and size of the starting fungal inoculum. In studies with Candida albicans, a few isolates have been identified that are markedly more resistant than other strains of the same species; in several in vivo studies of experimental infections, the more resistant isolates have caused infections less susceptible to fluconazole treatment. These findings corroborate a relation between in vitro and in vivo results. With further work it should be possible to define standard methods for use by clinical laboratories in determining fungal susceptibility to fluconazole.

UR - http://www.scopus.com/inward/record.url?scp=0025240568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025240568&partnerID=8YFLogxK

M3 - Article

C2 - 2184504

AN - SCOPUS:0025240568

VL - 12

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 3

ER -